FAQs

Columbia is collaborating with Deerfield, an investment firm dedicated to advancing healthcare, to accelerate the translation of research in Columbia faculty laboratories into clinical therapeutics. Hudson Heights is a Deerfield company that will support Columbia’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Hudson Heights will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases. Through Hudson Heights, Deerfield has committed up to $130 million in initial funding to support promising Columbia translational research. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Hudson Heights projects that show commercial potential.

Principal Investigators whose principal employer is Columbia University or Columbia University Irving Medical Center or who have a faculty appointment at Columbia University or Columbia University Irving Medical Center and are therefore subject to Columbia’s institutional policies are eligible to apply.

To submit an application, please contact the Columbia University Office of Intellectual Property and Technology Transfer.

No – We welcome applications from all therapeutic areas.